Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Metformin is an old drug. In its earliest form, it was an extract from lilacs and was purportedly used in the 1700s to treat ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

Are you on a weight loss journey but struggling to shed those extra kilos? You're not alone. Many people often feel lost about what to eat and do to reach their fitness goals, sometimes blindly ...